Martina M.D. Flammer Sells 37,828 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 37,828 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $78.61, for a total transaction of $2,973,659.08. Following the transaction, the insider now directly owns 100,165 shares in the company, valued at $7,873,970.65. This trade represents a 27.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Martina M.D. Flammer also recently made the following trade(s):

• On Thursday, February 6th, Martina M.D. Flammer sold 33,055 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $2,674,149.50.
• On Tuesday, January 14th, Martina M.D. Flammer sold 1,384 shares of Insmed stock. The stock was sold at an average price of $68.72, for a total transaction of $95,108.48.
• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total transaction of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04.

Insmed Stock Down 1.2 %

Shares of NASDAQ:INSM opened at $78.67 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $82.04. The company’s 50-day moving average price is $73.23 and its two-hundred day moving average price is $73.20. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $14.07 billion, a P/E ratio of -14.17 and a beta of 1.11.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Jennison Associates LLC lifted its position in Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC acquired a new position in Insmed during the 4th quarter valued at about $586,000. Orion Portfolio Solutions LLC lifted its position in Insmed by 48.5% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 9,170 shares during the period. Ally Bridge Group NY LLC lifted its position in Insmed by 16.9% during the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after purchasing an additional 21,833 shares during the period. Finally, Vestal Point Capital LP lifted its position in Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after purchasing an additional 850,000 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Guggenheim upped their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. JPMorgan Chase & Co. upped their target price on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Friday, February 7th. Finally, Morgan Stanley upped their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $85.60.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.